




Supplementary Figure 2. Progression-free survival and overall survival according to doxorubicin dose intensity administered. Progression-free survival according to RDDI in (A) intermediate-fit or frail patients ($n = 87$) and (B) fit patients ($n = 162$). Overall survival based on RDDI in (C) intermediate-fit or frail patients and (D) fit patients. RDDI, relative doxorubicin dose intensity; HR, hazard ratio; CI, confidence interval.